Chase TN - Search Results

1

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL. Hutton JT, et al. Among authors: chase tn. Mov Disord. 2001 May;16(3):459-63. doi: 10.1002/mds.1085. Mov Disord. 2001. PMID: 11391739 Clinical Trial.

2

Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.

Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN. Metman LV, et al. Among authors: chase tn. Mov Disord. 1996 May;11(3):257-60. doi: 10.1002/mds.870110307. Mov Disord. 1996. PMID: 8723141 Clinical Trial.

3

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Del Dotto P, et al. Among authors: chase tn. Mov Disord. 2001 May;16(3):515-20. doi: 10.1002/mds.1112. Mov Disord. 2001. PMID: 11391748 Clinical Trial.

4

Levodopa in the treatment of Parkinson's disease: a consensus meeting.

Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak P, Tolosa E, et al. Agid Y, et al. Mov Disord. 1999 Nov;14(6):911-3. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h. Mov Disord. 1999. PMID: 10584663 Review. No abstract available.

5

Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.

Metman LV, Hoff J, Mouradian MM, Chase TN. Metman LV, et al. Among authors: chase tn. Mov Disord. 1994 Jul;9(4):463-5. doi: 10.1002/mds.870090416. Mov Disord. 1994. PMID: 7969216 Clinical Trial.

6

Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.

Metman LV, Sethy VH, Roberts JR, Bravi D, Hoff JI, Mouradian MM, Chase TN. Metman LV, et al. Among authors: chase tn. Mov Disord. 1994 Sep;9(5):577-81. doi: 10.1002/mds.870090512. Mov Disord. 1994. PMID: 7990854 Clinical Trial.

7

Acute pharmacologic blockade of dyskinesias in Parkinson's disease.

Blanchet PJ, Metman LV, Mouradian MM, Chase TN. Blanchet PJ, et al. Among authors: chase tn. Mov Disord. 1996 Sep;11(5):580-1. doi: 10.1002/mds.870110516. Mov Disord. 1996. PMID: 8866502 No abstract available.

8

Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.

Metman LV, Konitsiotis S, Chase TN. Metman LV, et al. Among authors: chase tn. Mov Disord. 2000 Jan;15(1):3-8. doi: 10.1002/1531-8257(200001)15:1<3::aid-mds1003>3.0.co;2-e. Mov Disord. 2000. PMID: 10634235 Review. No abstract available.

9

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Metman LV, et al. Among authors: chase tn. Clin Neuropharmacol. 2001 May-Jun;24(3):163-9. doi: 10.1097/00002826-200105000-00008. Clin Neuropharmacol. 2001. PMID: 11391128

10

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.

Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Mouradian MM, et al. Among authors: chase tn. Ann Neurol. 1987 Oct;22(4):475-9. doi: 10.1002/ana.410220406. Ann Neurol. 1987. PMID: 3435068

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

451 results

Search Page